Compare NUVL & SYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | SYM |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 7.5B |
| IPO Year | 2021 | 2021 |
| Metric | NUVL | SYM |
|---|---|---|
| Price | $99.24 | $48.65 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 13 |
| Target Price | ★ $135.33 | $57.31 |
| AVG Volume (30 Days) | 443.1K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $2,246,922,000.00 |
| Revenue This Year | N/A | $24.75 |
| Revenue Next Year | $1,064.25 | $27.90 |
| P/E Ratio | ★ N/A | $2,661.00 |
| Revenue Growth | N/A | ★ 25.65 |
| 52 Week Low | $55.54 | $16.32 |
| 52 Week High | $113.02 | $87.88 |
| Indicator | NUVL | SYM |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 34.55 |
| Support Level | $98.65 | $48.60 |
| Resistance Level | $107.13 | $50.14 |
| Average True Range (ATR) | 4.05 | 2.69 |
| MACD | -0.31 | -0.29 |
| Stochastic Oscillator | 19.28 | 0.43 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.